A Phase 2 interventional study of sodium nitrite in Peripheral Arterial Disease, sponsored by TheraVasc Inc.. Completed at 10 sites in United States. Open to participants aged 35 Years to 85 Years. Per ClinicalTrials.gov, last updated 2020-04-21.
Sponsored by TheraVasc Inc. · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 479 studies in Peripheral Arterial Disease with a site in United States — 82 open to participants now, 101 under way, 10 of them phase 3. Peripheral Arterial Disease · United States.
Among the 479 studies in Peripheral Arterial Disease with a site in United States, this one is the 201st largest by enrollment of the 373 interventional ones that give a count, is one of 25 that started in 2011, is one of 48 in phase 2, and was the 88th registered.
1,377 studies on the registry are indexed under Peripheral Arterial Disease; 275 are open to participants now.
Browse Peripheral Arterial Disease studies →82 of the 479 studies in Peripheral Arterial Disease with a site in United States are open now. Recruiting first, the newest first:
Regeneron Pharmaceuticals · Sites in United States, United Kingdom
Ages 18+
Shanghai CureGene Pharmaceutical Co., Ltd. · Sites in United States
Ages 18–55 · Healthy volunteers
University of Tennessee Graduate School of Medicine · Sites in United States
Ages 18+
Cook Research Incorporated · Sites in United States
Ages 18+
University of Nebraska · Sites in United States
Ages 19+ · Healthy volunteers
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 192 Peripheral Arterial Disease studies recruiting now, 138 (72%) set no upper age limit and 9 (5%) stop at 75 or younger; 13 take children under 18; 19 take healthy volunteers.
This study: 35 Years to 85 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
479 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 49 · Phase 2 65 · Phase 3 35 · Phase 4 25
First in 1992; this study’s year is marked. 25 started in 2011.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 55 is below the median of 70 across 927 interventional studies indexed under Peripheral Arterial Disease.
Median enrollment 64 across the 373 interventional studies, 125 across the 103 observational. Of the 335 that completed or were terminated, 155 (46%) have results posted.
This tab as a report to print or save as PDF → With an account.
189 of 479 have an industry lead sponsor. The 10 most frequent:
TheraVasc Inc. is the lead sponsor of 2 studies on the registry; none are open to participants now.
TheraVasc Inc. has 1 study filed under Peripheral Arterial Disease — fewer than ten, so there is no comparison to draw.
36 of the studies in Peripheral Arterial Disease with a site in United States that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04794530Phase 3Northwestern UniversityThe COCOA-PAD II Trial | 2026-12-31 |
| NCT05132439Phase 3VA Office of Research and DevelopmentMetfOrmin BenefIts Lower Extremities With Intermittent Claudication | 2027-02-28 |
| NCT07639853Medtronic EndovascularCase-Specific Health Care Professional Clinical Survey for Concerto Versa™ Detachable Coils | 2026-11 |
| NCT06321575Nipro Vascular Innovations Americas, IncThe Golazo® Peripheral Atherectomy System for a Safe and Effective Atherectomy (GREAT Trial) | 2026-11 |
| NCT05916950Philips Clinical & Medical Affairs GlobalThe THOR IDE Study | 2026-12 |
Add all 36 to your calendar (.ics) → With an account.
Among the 479 studies in Peripheral Arterial Disease with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Sodium nitrite has been demonstrated to promote new blood vessel growth, speed up wound healing and prevent tissue necrosis in animals. Since patients with PAD experience many of these problems, this study will seek to determine whether this drug, when given orally, could provide the same benefits to patients with PAD.
Peripheral artery disease (PAD) is a manifestation of systemic atherosclerosis and a strong predictor of cardiovascular (CV) mortality. The systemic disease of atherosclerosis in these patients results in arterial stenoses in the arteries supplying the muscles of the lower extremities. During exercise, the stenoses limit the ability to increase blood flow, which leads to an oxygen supply/metabolic demand mismatch, a bio-energetic deficit, and subsequent muscle contractile dysfunction. Thus, the primary pathophysiology of PAD is related to the limitation in blood flow and abnormal hemodynamics (reduced tissue perfusion pressure and blood flow) of the lower limbs during exercise. Patients with PAD commonly present with symptoms of intermittent claudication (IC), often described by patients as a cramping, aching, or fatigue sensation in the calf muscles of the legs that occurs during physical activity. Notably, the symptom of claudication pain is due to exercise-induced ischemia in the muscles of the leg, causing a significant limitation of functional exercise capacity and adversely affecting quality of life.
Sodium nitrite is being investigated as a potential new therapy for improving function in patients with PAD. The overall goal of this dose-ranging study is to evaluate the safety, pharmacokinetics, tolerability, and potential biological activity of multiple doses of oral sodium nitrite in patients with PAD. As described above, the primary pathophysiology of PAD is related to the limitation in blood flow of the lower extremities, resulting in limited exercise tolerance and decreased quality of life. PAD is highly prevalent in patients with diabetes, leading to poor outcomes and accelerated disease progression compared with non-diabetic counter-parts. A common feature of both patient groups is endothelial dysfunction, decreased NO bioavailability, and depletion of NO stores, a finding that may be compounded when PAD and diabetic conditions coexist. Sodium nitrite is an inorganic salt that is found and metabolized in vivo. At physiological concentrations, sodium nitrite is known to cause vasodilation, a feature which is enhanced in hypoxic or ischemic environments. The nitrite anion acts a NO reservoir and can be readily converted to active NO by a non-enzymatic reaction with deoxyhemoglobin, making it a unique candidate for potential therapeutic effect in ischemic tissues. Accordingly, this study is designed to assess the safety and tolerability of sodium nitrite as well as the pharmacokinetic and pharmacodynamic relationship of sodium nitrite at two different doses versus placebo. Sodium nitrite's effects on endothelial function, a marker of NO bioactivity, and measures of functional walking capacity will also be assessed.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
TIA (transient ischaemic attack)
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Microcrystalline cellulose NF at 60 mg/capsule, BID
Drug: sodium nitrite
40 mg dose, BID
Drug: sodium nitrite
80 mg dose, BID
Drug: sodium nitrite
0, 40 or 80 mg twice each day for 10 weeks followed by a 1 week escalation of 2 times the dose.
Also known as: TV1001
Reporting of Adverse Events During 11 Week Treatment Period.
The primary objective of this clinical study is to evaluate the safety and tolerability of multiple doses of twice daily 40mg and 80mg sodium nitrite compared with placebo over a 10 week treatment period. Subjects will be asked to report any adverse events during the trial period, and blood pressure, methemoglobin levels and other blood chemistries will be assessed during the trial period for changes from baseline.
Time frame: 11 weeks
Assessment of Changes in Brachial Artery Flow-Mediated Dilation (FMD)at 10 Weeks From Baseline
Demonstrate the pharmacodynamic effect of sodium nitrite on changes in FMD by imaging before investigational product administration and 10 weeks after administration of investigational product but before dose escalation. FMD was measured at baseline and again after 10 weeks of treatment. The value at ten weeks was subtracted from the baseline value. A negative value represents a worsening of FMD while a positive value represents an improvement in FMD.
Time frame: 10 weeks
Assessment of Changes in Walking Distance.
Demonstrate the pharmacodynamic effect of sodium nitrite on changes in functional measures of walking distance. The distance a subject can walk in 6 minutes will be measured prior to the first administration of the investigational product and 10 weeks after taking the investigational product but before the dose escalation. Distance walked in 6 minutes was measured at baseline and again after 10 weeks of treatment. The distance walked at ten weeks was subtracted from the baseline distance walked. A negative value represents a worsening of walking distance while a positive value represents an improvement in walking distance.
Time frame: 10 weeks
Assessment of Improvement of Quality of Life Using the WIQ (Walking Impairment Questionnaire) and SF-36 Questionnaire.
Demonstrate the pharmacodynamic effect of sodium nitrite on changes in measures of claudication symptoms using Quality of Life questionnaires (WIQ \& RAND SF-36). The WIQ is a disease-specific instrument that measures community-based walking. The questionnaire consists of four subscales (pain severity, distance, speed, and stairs). The SF-36 is a set of 36 questions that the subject provides short answers on concerning general health issues that the subject chooses. Questionnaires were administered at baseline and again after 10 weeks of treatment. Scores from the individual sections were summed and divided by the maximal score for the section to obtain a percent score, ranging from 0 (inability to perform task) to 100 (no difficulty). The scores for each section at ten weeks was subtracted from the baseline scores for each section of the questionnaires. A negative represents declining function, a positive value represents improvement over the study period.
Time frame: 10 weeks
| Milestone | Placebo | 40 mg Sodium Nitrite | 80 mg Sodium Nitrite |
|---|---|---|---|
| Started | 18 | 19 | 18 |
| Completed | 15 | 17 | 15 |
| Not completed | 3 | 2 | 3 |
The primary objective of this clinical study is to evaluate the safety and tolerability of multiple doses of twice daily 40mg and 80mg sodium nitrite compared with placebo over a 10 week treatment period. Subjects will be asked to report any adverse events during the trial period, and blood pressure, methemoglobin levels and other blood chemistries will be assessed during the trial period for changes from baseline.
| participants | Placebo | 40 mg Sodium Nitrite | 80 mg Sodium Nitrite |
|---|---|---|---|
| at least 1 AE | 9 | 12 | 14 |
| SAEs | 2 | 0 | 0 |
Demonstrate the pharmacodynamic effect of sodium nitrite on changes in FMD by imaging before investigational product administration and 10 weeks after administration of investigational product but before dose escalation. FMD was measured at baseline and again after 10 weeks of treatment. The value at ten weeks was subtracted from the baseline value. A negative value represents a worsening of FMD while a positive value represents an improvement in FMD.
| percentage from baseline in FMD | Placebo | 40 mg Sodium Nitrite | 80 mg Sodium Nitrite |
|---|---|---|---|
| Intent to Treat Population | -2.41 ± 6.20 | -0.93 ± 4.58 | 0.06 ± 3.15 |
| Per Protocol Population | -2.69 ± 6.50 | -0.69 ± 4.65 | 0.50 ± 3.28 |
Demonstrate the pharmacodynamic effect of sodium nitrite on changes in functional measures of walking distance. The distance a subject can walk in 6 minutes will be measured prior to the first administration of the investigational product and 10 weeks after taking the investigational product but before the dose escalation. Distance walked in 6 minutes was measured at baseline and again after 10 weeks of treatment. The distance walked at ten weeks was subtracted from the baseline distance walked. A negative value represents a worsening of walking distance while a positive value represents an improvement in walking distance.
| Feet | Placebo | 40 mg Sodium Nitrite | 80 mg Sodium Nitrite |
|---|---|---|---|
| Assessment of Changes in Walking Distance. | 7.35 ± 124.67 | 47.39 ± 180.46 | -28.82 ± 259.59 |
Demonstrate the pharmacodynamic effect of sodium nitrite on changes in measures of claudication symptoms using Quality of Life questionnaires (WIQ \& RAND SF-36). The WIQ is a disease-specific instrument that measures community-based walking. The questionnaire consists of four subscales (pain severity, distance, speed, and stairs). The SF-36 is a set of 36 questions that the subject provides short answers on concerning general health issues that the subject chooses. Questionnaires were administered at baseline and again after 10 weeks of treatment. Scores from the individual sections were summed and divided by the maximal score for the section to obtain a percent score, ranging from 0 (inability to perform task) to 100 (no difficulty). The scores for each section at ten weeks was subtracted from the baseline scores for each section of the questionnaires. A negative represents declining function, a positive value represents improvement over the study period.
| units on a scale | Placebo | 40 mg Sodium Nitrite | 80 mg Sodium Nitrite |
|---|---|---|---|
| WIQ: Walking Distance | -1.07 (-14.2 to 45.6) | 2.13 (-70.3 to 63.4) | 5.05 (-66.5 to 61.8) |
| WIQ: Walking Speed | 0.00 (-23.9 to 38.0) | 6.52 (-17.4 to 51.5) | 7.07 (-57.6 to 28.3) |
| WIQ: Stair Climbing | 0.0 (-41.7 to 45.8) | 12.5 (-25.0 to 58.3) | 0.0 (-37.5 to 45.8) |
| SF-36: Physical Functioning | 0.0 (-20.0 to 15.0) | 5.0 (-25.0 to 35.0) | 0.0 (-35.0 to 30.0) |
| SF-36: Limitations due to Physcial Health | 25.0 (-75.0 to 50) | 0.0 (-75.0 to 100) | 0.0 (-100.0 to 50) |
| SF-36: Limitations due to Emotional Health | 0.0 (-100.0 to 100.0) | 0.00 (-100.0 to 100.0) | 0.0 (-100.0 to 66.7) |
| SF-36: Energy/Fatigue | -2.50 (-25.0 to 20.0) | 0.0 (-25.0 to 65.0) | 5.0 (-30.0 to 30.0) |
| SF-36: Emotional Well Being | -4.0 (-44.0 to 20.0) | 2.0 (-24.0 to 48.0) | 4.0 (-12.0 to 32.0) |
| SF-36: Social Functioning | 0.0 (-25.0 to 12.5) | 0.0 (-25.0 to 62.5) | 0.0 (-37.5 to 50.0) |
| SF-36: Pain | 0.0 (-55.0 to 22.5) | 12.5 (-12.5 to 55.0) | 0.0 (-37.5 to 22.5) |
| SF-36: General Health | 0.0 (-25.0 to 20.0) | 7.5 (-15.0 to 25.0) | 0.0 (-20.0 to 30.0) |
Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Placebo | — | 2/18 (11.1%) | 9/18 (50%) |
| 40 mg Sodium Nitrite | — | 0/19 (0%) | 12/19 (63.2%) |
| 80 mg Sodium Nitrite | — | 0/18 (0%) | 14/18 (77.8%) |
| Event | Placebo | 40 mg Sodium Nitrite | 80 mg Sodium Nitrite |
|---|---|---|---|
| Worsening PADVascular disorders | 1/18 | 0/19 | 0/18 |
| GI BleedGastrointestinal disorders | 1/18 | 0/19 | 0/18 |
| Event | Placebo | 40 mg Sodium Nitrite | 80 mg Sodium Nitrite |
|---|---|---|---|
| Headaches and dizzinessGeneral disorders | 0/18 | 4/19 | 8/18 |
| GI DisordersGastrointestinal disorders | 4/18 | 2/19 | 3/18 |
| InvestigationsInvestigations | 3/18 | 1/19 | 3/18 |
| Muscoskeletal and Connective TissuesMusculoskeletal and connective tissue disorders | 2/18 | 3/19 | 2/18 |
| InfectionsInfections and infestations | 1/18 | 2/19 | 1/18 |
| Age, Continuous(years) | Placebo | 40 mg Sodium Nitrite | 80 mg Sodium Nitrite | Total |
|---|---|---|---|---|
| Mean | 64.9 ± 8.98 | 65.3 ± 8.86 | 67.9 ± 9.99 | 66.0 ± 9.21 |
| Age, Categorical(Participants) | Placebo | 40 mg Sodium Nitrite | 80 mg Sodium Nitrite | Total |
|---|---|---|---|---|
| <=18 years | 0 | 0 | 0 | 0 |
| Between 18 and 65 years | 6 | 11 | 4 | 21 |
| >=65 years | 12 | 8 | 14 | 34 |
| Sex: Female, Male(Participants) | Placebo | 40 mg Sodium Nitrite | 80 mg Sodium Nitrite | Total |
|---|---|---|---|---|
| Female | 5 | 4 | 5 | 14 |
| Male | 13 | 15 | 13 | 41 |
| Region of Enrollment(participants) | Placebo | 40 mg Sodium Nitrite | 80 mg Sodium Nitrite | Total |
|---|---|---|---|---|
| United States | 18 | 19 | 18 | 55 |
The record gives a start of Jul 2011, a primary completion of Jan 2013 and a completion of Jan 2013. It does not say whether these dates are actual or estimated.
Results were first posted in Jul 2014, 1 year 6 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Apr 2020. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Sodium Nitrite
TheraVasc Inc.